RPRX Royalty Pharma margins

Relative Growth: Rel. Growth: 59

Relative Strength: Rel. Strength: 90

Relative Valuation: Rel. Valuation: 16

Relative Profitability: Rel. Profitability: 77

Gross margin

100%

Operating margin

59.6%

EBITDA margin

46.4%

Net margin

32.1%

Based on the latest figures, Royalty Pharma reports a gross margin of 100%, an operating margin of 59.6%, an EBITDA margin of 46.4%, and a net margin of 32.1%. Operating margin led the reported margin declines with 20.2 percentage points, while the other margins did not change.

RPRX margin history

Gross, operating, EBITDA and net margin trends

Over the last 3 years, Royalty Pharma recorded average margins of 100% gross, 62.97% operating, 49.58% EBITDA, and 38.75% net. Royalty Pharma's current performance shows that operating, EBITDA, and net margins are below their three-year averages.

RPRX margin expansion

Year-over-year margin changes in percentage points

From the same period last year, operating margin contracted by 20.2 percentage points, EBITDA margin by 9.6 percentage points, and net margin by 12.3 percentage points, while gross margin was unchanged.

Gross margin expansion

0pp

Operating margin expansion

-20.2pp

EBITDA margin expansion

-9.6pp

Net margin expansion

-12.3pp

RPRX Gross margin

The average gross margin for Royalty Pharma was 100% in the last 3 years. Royalty Pharma's current gross margin is 100% and is in line with its three-year average. The gross margin for Royalty Pharma moved between 100% in Dec 2023 and 100% in Jun 2026.

RPRX Operating margin

Looking back over the last 3 years, Royalty Pharma recorded an average operating margin of 62.97%. Royalty Pharma's current operating margin is 59.6% and is 3.4 percentage points below its three-year average. The highest operating margin for Royalty Pharma was 83.9% in Mar 2025, while the lowest was 42% in Mar 2024.

RPRX EBITDA margin

Reviewing the last 3 years, Royalty Pharma recorded an average EBITDA margin of 49.58%. Royalty Pharma's current EBITDA margin is 46.4% and is 3.2 percentage points below its three-year average. The highest EBITDA margin for Royalty Pharma was 59.7% in Sep 2024, while the lowest was 38.4% in Jun 2024.

RPRX Net margin

Over the last 3 years, the average net margin for Royalty Pharma was 38.75%. The latest net margin for Royalty Pharma is 32.1%, 6.7 percentage points below its three-year average. Royalty Pharma's net margin ranged from a low of 30.1% in Jun 2024 to a high of 50.5% in Sep 2024.

RPRX margin group comparison

Margins compared with peer-group, industry and sector averages

With a gross margin of 100%, RPRX ranks higher than the Healthcare sector and the industry average. In comparison with the Healthcare sector average of 68.3%, Royalty Pharma's gross margin is 46% higher.

RPRX margin peer comparison

Compare margins with selected peers

Frequently asked questions

What is Royalty Pharma's gross margin?

As of Jun 30, 2026, RPRX has a gross margin of 100%.

What is Royalty Pharma's operating margin?

For the period ending Jun 30, 2026, RPRX recorded an operating margin of 59.6%.

What is Royalty Pharma's EBITDA margin?

For the period ending Jun 30, 2026, RPRX recorded an EBITDA margin of 46.4%.

What is Royalty Pharma's net margin?

The current net margin for RPRX is 32.1% as of Jun 30, 2026.

What are the average margins of RPRX?

Looking back over 3 years, RPRX recorded average margins of 100.0% gross, 63.0% operating, 49.6% EBITDA, and 38.8% net.

What are the highest historical margins of RPRX?

Looking back across 5 years, RPRX reached 100% gross in Jun 2026, 83.9% operating in Mar 2025, 59.7% EBITDA in Sep 2024, and 50.5% net in Sep 2024.

What are the lowest historical margins of RPRX?

Over this 5-year history, Royalty Pharma's margins fell as low as 100% gross in Dec 2021, 13.7% operating in Dec 2022, 10.3% EBITDA in Dec 2022, and 1.9% net in Dec 2022.